A specific five-amino-acid peptide called ETLVK, produced by probiotic bacteria, was identified as the key molecule responsible for reducing obesity and improving lipid metabolism in mice.
ETLVK confirmed as key peptideAmong five candidate peptides predicted from the probiotic protein sequence, mass spectrometry confirmed ETLVK as the primary molecule responsible for lipid-lowering activity
What the researchers found
The probiotic bacterium L. plantarum TCCC11824 produces bioactive peptides that reduce obesity in mice fed a high-fat diet. The crushed bacterial supernatant (LpS) significantly improved blood lipid profiles, reduced liver injury, suppressed inflammation in liver and fat tissue, decreased ectopic fat accumulation, and positively shifted gut microbiota composition.
Researchers identified that the 3-10 kDa fraction of LpS strongly inhibited pancreatic cholesterol esterase and lipase and suppressed HMGCR expression in lipid-disordered cells. Among five predicted candidate peptides (IPR, IEK, PGDR, ETLVK, and QAEQLR), LC-MS/MS confirmed ETLVK as the key peptide responsible for the lipid-lowering effect.
Why it matters
Understanding exactly which molecules from probiotic bacteria produce health benefits has been a major challenge. This study pinpoints a specific five-amino-acid peptide (ETLVK) as a key active component, providing a molecular explanation for how this probiotic fights obesity. This could lead to targeted peptide-based therapies for metabolic disorders rather than relying on whole probiotic formulations.
The numbers in context
5 candidate peptides predicted · ETLVK confirmed as key active peptide · 3-10 kDa bioactive fraction · Inhibited pancreatic cholesterol esterase + lipase · Suppressed HMGCR expression
How the study worked
Researchers fed mice a high-fat diet to induce obesity, then treated them with crushed supernatant from L. plantarum TCCC11824. They analyzed blood lipids, liver injury markers, inflammation, fat distribution, and gut microbiota composition. The active fraction was identified through ultrafiltration, and candidate peptides were predicted using bioinformatics from the full-length protein sequence and confirmed via LC-MS/MS mass spectrometry.
Who was studied
C57BL/6 mice fed a high-fat diet (obesity model)
What this study cannot tell us
This is an animal study in mice; effects in humans remain unconfirmed. The study used a bacterial supernatant rather than a purified peptide for most in vivo experiments. The long-term effects and optimal dosing of ETLVK itself have not been established.
How to read the evidence
This is a preclinical animal study with strong mechanistic investigation, combining in vivo mouse experiments with in vitro enzyme inhibition assays, bioinformatics predictions, and mass spectrometry confirmation. Human studies are needed for clinical translation.
When this study was published
Published in 2025, this is very recent research at the forefront of postbiotic peptide identification and metabolic disease research.
The bigger picture
The probiotics industry has grown enormously, but the science behind how specific bacteria produce health benefits often remains unclear. This study represents a shift toward precision — identifying the exact peptide molecules that drive metabolic improvements. This approach could lead to postbiotic therapies: purified bioactive peptides that provide the benefits of probiotics without the need for live bacteria.
Questions still open
- Can the purified ETLVK peptide alone reproduce the full anti-obesity effects seen with the complete bacterial supernatant?
- Would ETLVK be effective when taken orally in humans, or would it be degraded in the digestive tract?
- Do other probiotic species produce similar bioactive peptides that could be combined for enhanced metabolic benefits?
Common questions
What is a postbiotic and how is it different from a probiotic?
How does the ETLVK peptide reduce obesity?
Read the original research
Postbiotic-Mediated Obesity Reduction via Bioactive Peptide ETLVK and Gut Microbiota in HFD Mice.
Journal of agricultural and food chemistry, 73(36), 22436-22447
Citation
Da, Jia-Yi; Wang, Chang; Feng, Xiaomin; Li, Han-Lu; Zhong, Feiliang; Luo, Xue-Gang. (2025). Postbiotic-Mediated Obesity Reduction via Bioactive Peptide ETLVK and Gut Microbiota in HFD Mice.. Journal of agricultural and food chemistry, 73(36), 22436-22447. https://doi.org/10.1021/acs.jafc.5c07319